Evaluation of Voriconazole Pharmacodynamics Using Time-Kill Methodology

ABSTRACT Voriconazole is an investigational azole antifungal agent with activity against a variety of fungal species, including fluconazole-susceptible and -resistant Candida species andCryptococcus neoformans. In this study, we employed in vitro time-kill methods to characterize the relationship between concentrations of voriconazole and its fungistatic activity againstCandida albicans, Candida glabrata,Candida tropicalis, and C. neoformans. Isolates were exposed to voriconazole concentrations ranging from 0.0625 to 16 times the MIC, and the viable colony counts were determined over time. The 50 and 90% effective concentrations (EC50 and EC90, respectively) were determined at 8, 12, and 24 h following the addition of voriconazole. At each time point, near-maximal fungistatic activity, as indicated by the EC90, was noted at a drug concentration of approximately three times the MIC. Additionally, EC50 and EC90 did not change over time, thus suggesting that the rate of activity was not improved by increasing concentrations. Voriconazole exhibits non-concentration-dependent pharmacodynamic characteristics in vitro.

[1]  M. Klepser,et al.  Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. , 1998, The Journal of antimicrobial chemotherapy.

[2]  Ronald N. Jones,et al.  Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans , 1997, Antimicrobial agents and chemotherapy.

[3]  C. Kauffman,et al.  In vitro activity of voriconazole against Candida species. , 1998, Diagnostic microbiology and infectious disease.

[4]  M. Pfaller,et al.  In Vitro Activities of Voriconazole (UK-109,496) and Four Other Antifungal Agents against 394 Clinical Isolates ofCandida spp , 1998, Antimicrobial Agents and Chemotherapy.

[5]  R. Pearson,et al.  Method of reliable determination of minimal lethal antibiotic concentrations , 1980, Antimicrobial Agents and Chemotherapy.

[6]  M. Ghannoum,et al.  Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species , 1997, Antimicrobial agents and chemotherapy.

[7]  M. Ghannoum,et al.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  R. Haubrich,et al.  Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Russell E. Lewis,et al.  Influence of Test Conditions on Antifungal Time-Kill Curve Results: Proposal for Standardized Methods , 1998, Antimicrobial Agents and Chemotherapy.

[10]  Michael H. Miller,et al.  Pharmacodynamics of Fluconazole in a Murine Model of Systemic Candidiasis , 1998, Antimicrobial Agents and Chemotherapy.

[11]  D. Andes,et al.  Characterization and Quantitation of the Pharmacodynamics of Fluconazole in a Neutropenic Murine Disseminated Candidiasis Infection Model , 1999, Antimicrobial Agents and Chemotherapy.